This year the European Society of Cardiology (ESC) 2023 Congress is being held in Amsterdam, The Netherlands from August 25 – 28 both onsite and online. The international cardiology community will gather to learn about cutting edge science, new guidelines and important developments in cardiovascular research. Hereby we provide an overview of what to expect at the ESC Congress 2023.
There will be 30 hot line presentations presented over the 4 day congress. Topics range anywhere from HFpEF subgroups to OCT vs angiography or IVUS trials, as well as multivessel immediate versus staged revascularization in STEMI.
Hereby are the headlines of the 9 Hot Line sessions.
August 25th, Hot Line 1 Session:
STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity
NOAH-AFNET 6: Oral anticoagulation in patients with atrial high rate episodes
COP-AF – Colchicine for the prevention of perioperative atrial fibrillation after major thoracic surgery
August 26th, Hot Line 2 Session:
Qiliqiangxin in patients with heart failure and reduced ejection fraction – the QUEST study
BUDAPEST CRT Upgrade: Cardiac resynchronisation therapy upgrade in heart failure with right ventricular pacing – a multicentre, randomised, controlled trial
HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency
Effects of FCM on recurrent HF hospitalizations: an individual participant data meta-analysis
August 26th, Hot Line 3 Session:
FIRE trial: Physiology-Guided Complete PCI in Older MI Patients
ECLS-SHOCK – venoarterial membrane oxygenation in cardiogenic shock
STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention
August 27th, Hot Line 4 Session:
ILUMIEN IV: OCT Versus Angiography
OCT-guided or angiography-guided PCI in complex bifurcation lesions. The OCTOBER trial
OCTIVUS: OCT- vs. IVUS-Guided PCI
OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis
August 27th, Hot Line 5 Session:
ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy
ARREST trial: Expedited transfer to a cardiac arrest center for OHCA
ADVENT: Pulsed Field Ablation vs Thermal Ablation (RF/Cryo) for Paroxysmal AF
August 27th, Hot Line 6 Session:
MULTISTARS AMI: Multivessel immediate versus staged revascularization in STEMI
CASTLE-HTx: Catheter Ablation versus Medical Therapy to Treat Atrial Fibrillation in End-stage Heart Failure
The FRAIL-AF randomized controlled trial
August 28th, Hot Line 7 Session:
Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial
ARAMIS – Anakinra versus Placebo in Acute Myocarditis
DANPACE II – Reducing atrial pacing in Sinus Node Disease
August 28th, Hot Line 8 Session:
RED-CVD: Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and COPD
NITRATE-CIN – Inorganic nitrate to prevent CIN after angiography for ACS
DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure
PUSH-AHF: Natriuresis guided therapy in acute heart failure
August 28th, Hot Line 9 Session:
RIGHT: Prolongation of anticoagulation after Primary PCI
ONCO DVT Study; Optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer study
Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19
What else can we expect at ESC Congress 2023?
Further to the state-of-the-art research being presented, we can expect some ESC guideline updates. This includes updates to the management of endocarditis, cardiovascular disease in diabetic patients, cardiomyopathies, acute coronary syndrome as well as a 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.